Mayne Pharma Group (ASX: MYX) — Company Overview, News & Financial Data
Mayne Pharma is an Australian specialty pharmaceutical company focused on branded and generic pharmaceuticals.
Mayne Pharma Group
Mayne Pharma Group is a specialty pharmaceutical company focused on commercialising branded and generic prescription products globally. With a history spanning more than 40 years in oral drug delivery innovation, the company develops, manufactures, and markets pharmaceutical products across key therapeutic areas, including women's health and dermatology. Mayne Pharma Group operates commercial and manufacturing infrastructure in Australia and North America, delivering novel oral and topical dose formulations. In addition to commercialising its proprietary pharmaceutical portfolio, the business provides contract development and manufacturing services, offering analytical testing, formulation, and commercial scale manufacturing to external pharmaceutical partners worldwide.
Snapshot
Operations
Products and/or services of Mayne Pharma Group
- Women's Health Pharmaceuticals: Commercial distribution of branded prescription medications, oral contraceptives, and specialized supplements designed for women's healthcare needs across retail and specialty pharmacy networks in key markets including North America and Australia.
- Dermatology Therapeutics: Development and commercial supply of specialized topical and oral dermatological pharmaceuticals targeting various skin conditions, distributed through wholesale channels, healthcare provider networks, and retail pharmacies across key global target markets.
- Generic Prescription Medicines: Commercialization of a portfolio of generic prescription drugs in solid oral and topical dosage forms, serving hospital systems, wholesalers, and retail pharmacies across Australia and North America.
- Contract Development and Manufacturing Services: Full-service pharmaceutical CDMO capabilities supplying custom formulation development, analytical testing, pilot manufacturing, and commercial-scale production of complex oral and topical dose forms for global pharmaceutical clients.
- Bioavailability and Specialty Technologies: Utilization of proprietary oral dosage drug delivery platforms, including controlled release delivery systems and solubility enhancement technologies, to optimize active pharmaceutical ingredient stability and patient compliance.
- Australian Commercial Operations: Distribution and marketing of branded specialty pharmaceuticals, OTC healthcare products, and prescription drugs throughout the Australian market via network logistics hubs, pharmaceutical wholesalers, and community retail pharmacy chains.
Mayne Pharma Group executive team
- Aaron GrayChief Executive Officer
- Griffin D. BuchananChief Financial Officer
- Thomas DuthyManager of Investor Relations
- Kimberly ParkerExecutive VP & General Counsel
- Brant SchofieldExecutive Vice President of Corporate Development
- Kate SurdezVP & Global Head of Human Resources
- Daniel MoorePresident of DistributeRx
- Frank CastyExecutive VP, Global Head of R&D and Chief Medical Officer
- Tony RamyExecutive Vice President of Women's Health
- Brenton WalterFinancial Controller